Resverlogix Corp. and the Resverlogix BETonMACE Clinical Steering Committee (CSC), represented by Professor Kausik Ray (Chair), announced the FDA acceptance of the Company’s Phase 3 BETonMACE trial Protocol amendments. The BETonMACE trial will now be expanded beyond Europe, Asia and South America to a fourth continent – North America with the addition of the United States. The CSC is responsible for oversight and strategic direction for the Company’s Phase 3 BETonMACE trial. The study is a large international multicenter, double-blind, randomized, parallel group, placebo-controlled clinical trial to determine whether treatment with apabetalone in combination with rosuvastatin or atorvastatin increases the time to MACE compared to treatment with rosuvastatin or atorvastatin alone. The primary endpoint of the BETonMACE trial is designed to show a relative risk reduction of MACE, narrowly defined as a single composite endpoint of cardiovascular death, non-fatal myocardial infarction (“MI”) and stroke. The study is an event-based trial and will continue until at least 250 MACE events have occurred. The study will ultimately contain at least 2,400 patients in 14 participating countries.